These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 16723548

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. In vitro activities of mutant prevention concentration-targeted concentrations of fluoroquinolones against Staphylococcus aureus in a pharmacodynamic model.
    Allen GP, Kaatz GW, Rybak MJ.
    Int J Antimicrob Agents; 2004 Aug; 24(2):150-60. PubMed ID: 15288314
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Mechanism of quinolone resistance in Staphylococcus aureus.
    Tanaka M, Wang T, Onodera Y, Uchida Y, Sato K.
    J Infect Chemother; 2000 Sep; 6(3):131-9. PubMed ID: 11810552
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Pharmacodynamic activity of fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae.
    Zhanel GG, Roberts D, Waltky A, Laing N, Nichol K, Smith H, Noreddin A, Bellyou T, Hoban DJ.
    J Antimicrob Chemother; 2002 May; 49(5):807-12. PubMed ID: 12003975
    [Abstract] [Full Text] [Related]

  • 10. Comparative pharmacodynamics of gatifloxacin and ciprofloxacin in an in vitro dynamic model: prediction of equiefficient doses and the breakpoints of the area under the curve/MIC ratio.
    Vostrov SN, Kononenko OV, Lubenko IY, Zinner SH, Firsov AA.
    Antimicrob Agents Chemother; 2000 Apr; 44(4):879-84. PubMed ID: 10722485
    [Abstract] [Full Text] [Related]

  • 11. [A study on the resistance of Staphylococcus aureus and the mechanisms of its resistance to fluoroquinolone].
    Lei Y, Gui X, Feng G.
    Zhonghua Nei Ke Za Zhi; 2001 Mar; 40(3):176-9. PubMed ID: 11798575
    [Abstract] [Full Text] [Related]

  • 12. Enrichment of fluoroquinolone-resistant Staphylococcus aureus: oscillating ciprofloxacin concentrations simulated at the upper and lower portions of the mutant selection window.
    Firsov AA, Lubenko IY, Smirnova MV, Strukova EN, Zinner SH.
    Antimicrob Agents Chemother; 2008 Jun; 52(6):1924-8. PubMed ID: 18378704
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. In vitro activities of novel nonfluorinated quinolones PGE 9262932 and PGE 9509924 against clinical isolates of Staphylococcus aureus and Streptococcus pneumoniae with defined mutations in DNA gyrase and topoisomerase IV.
    Jones ME, Critchley IA, Karlowsky JA, Blosser-Middleton RS, Schmitz FJ, Thornsberry C, Sahm DF.
    Antimicrob Agents Chemother; 2002 Jun; 46(6):1651-7. PubMed ID: 12019071
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Activities of ciprofloxacin and moxifloxacin against Stenotrophomonas maltophilia and emergence of resistant mutants in an in vitro pharmacokinetic-pharmacodynamic model.
    Ba BB, Feghali H, Arpin C, Saux MC, Quentin C.
    Antimicrob Agents Chemother; 2004 Mar; 48(3):946-53. PubMed ID: 14982788
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Pharmacodynamic activity of garenoxacin against ciprofloxacin-resistant Streptococcus pneumoniae.
    Zhanel GG, James J, Derkatch S, Laing N, Noreddin AM, Hoban DJ.
    J Antimicrob Chemother; 2006 Jul; 58(1):112-6. PubMed ID: 16644764
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.